Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.

To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Y. M., Byun, B. H., Choi, J. Y., Bae, S. H., Kim, B. S., So, H. S., Ryu, W. S.
Formato: Texto
Lenguaje:English
Publicado: Korean Academy of Medical Sciences 1999
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054362/
https://www.ncbi.nlm.nih.gov/pubmed/10331562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3054362/
https://www.ncbi.nlm.nih.gov/pubmed/10331562

Ejemplares similares